- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06109311
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
April 15, 2024 updated by: Eli Lilly and Company
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
The main purpose of this study is to determine the safety and efficacy of orforglipron.
Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor.
The study will last about 46 weeks and may include up to 20 visits.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
520
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Phone Number: 1-317-615-4559
- Email: ClinicalTrials.gov@lilly.com
Study Locations
-
-
-
Rio de Janeiro, Brazil, 20241-180
- Recruiting
- IBPClin - Instituto Brasil de Pesquisa Clínica
-
Principal Investigator:
- JOSELITA FRANÇA DE SIQUEIRA BODART
-
-
Distrito Federal
-
Brasília, Distrito Federal, Brazil, 70200730
- Recruiting
- L2IP - Instituto de Pesquisas Clínicas - FC072920211954380192
-
Principal Investigator:
- Eduardo Freire Vasconcellos
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brazil, 29055450
- Recruiting
- CEDOES
-
Principal Investigator:
- queulla garret santos
-
-
Paraná
-
Curitiba, Paraná, Brazil, 80040-110
- Recruiting
- Pesquisa Clínica em Diabetes - Dra Rosângela Réa
-
Principal Investigator:
- Rosangela Rea
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90560-003
- Recruiting
- Insight Centro de Pesquisas
-
Principal Investigator:
- Cassiane Bonato
-
-
São Paulo
-
Sao Bernardo do Campo, São Paulo, Brazil, 09715-090
- Recruiting
- Centro Multidisciplinar de Estudos Clinicos
-
Principal Investigator:
- Claudia de Brito
-
-
-
-
Anhui
-
Hefei, Anhui, China, 230011
- Recruiting
- The Second People's Hospital of Hefei
-
Principal Investigator:
- Jun Ye
-
Wuhu, Anhui, China, 241001
- Recruiting
- Wannan Medical College Yijishan Hospital
-
Principal Investigator:
- Jialin Gao
-
-
Beijing
-
Beijing, Beijing, China, 100051
- Recruiting
- Beijing Hospital
-
Principal Investigator:
- Lixin Guo
-
-
Chongqing
-
Chongqing, Chongqing, China, 400014
- Recruiting
- Chongqing General Hospital
-
Principal Investigator:
- Hongman Wang
-
-
Henan
-
Luoyang Shi, Henan, China, 471003
- Recruiting
- The First Affiliated Hospital of Henan University of Science &Technology
-
Principal Investigator:
- Hongwei Jiang
-
Zhengzhou, Henan, China, 450014
- Recruiting
- The Second Affiliated Hospital of Zhengzhou University
-
Principal Investigator:
- Qingju Li
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210011
- Recruiting
- The Second Affiliated Hospital of Nanjing Medical University
-
Principal Investigator:
- Yibing Lu
-
Nanjing, Jiangsu, China, 210012
- Recruiting
- Nanjing First Hospital
-
Principal Investigator:
- Jianhua Ma
-
Zhenjiang, Jiangsu, China, 212000
- Recruiting
- Affiliated Hospital of Jiangsu University
-
Principal Investigator:
- Guoyue Yuan
-
-
Shandong
-
Jinan, Shandong, China, 250013
- Recruiting
- Jinan Central Hospital
-
Principal Investigator:
- Xiaolin Dong
-
-
-
-
-
Oita, Japan, 870-0039
- Recruiting
- Abe Clinic
-
Principal Investigator:
- Katsushige Abe
-
Osaka, Japan, 553-0003
- Recruiting
- Kansai Electric Power Hospital
-
Principal Investigator:
- Yoshiyuki Hamamoto
-
-
Chiba
-
Mihama-ku,Chiba City, Chiba, Japan, 261-0004
- Recruiting
- Tokuyama clinic
-
Principal Investigator:
- Takahiko Tokuyama
-
-
Hokkaido
-
Chitose, Hokkaido, Japan, 066-0032
- Recruiting
- Hasegawa Medical Clinic
-
Principal Investigator:
- Atsushi Hasegawa
-
-
Ibaraki
-
Mito, Ibaraki, Japan, 311-4153
- Recruiting
- MinamiAkatsukaClinic
-
Principal Investigator:
- Hideo Takahashi
-
-
Kanagawa
-
Ebina, Kanagawa, Japan, 243-0432
- Recruiting
- Matoba Internal Medicine Clinic
-
Principal Investigator:
- Kiyokazu Matoba
-
Kamakura-shi, Kanagawa, Japan, 247-0056
- Recruiting
- Takai Internal Medicine Clinic
-
Principal Investigator:
- Masahiko Takai
-
-
Osaka
-
Kashiwara, Osaka, Japan, 582-0005
- Recruiting
- Shiraiwa Medical Clinic
-
Principal Investigator:
- Toshihiko Shiraiwa
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0031
- Recruiting
- Fukuwa Clinic
-
Principal Investigator:
- Yasushi Fukushima
-
Chuo-ku, Tokyo, Japan, 103-0002
- Recruiting
- The Institute for Adult Disease, Asahi Life Foundation
-
Principal Investigator:
- Yukiko Onishi
-
Ootaku, Tokyo, Japan, 143-0015
- Recruiting
- Medical Corporation Sato Medical clinic
-
Principal Investigator:
- Nobuyuki Sato
-
Tama, Tokyo, Japan, 206-0633
- Recruiting
- Tama Center Clinic Mirai
-
Principal Investigator:
- Hitomi Fujii
-
-
-
-
-
Caguas, Puerto Rico, 00725
- Recruiting
- Centro de Endocrinologia y Nutricion
-
Principal Investigator:
- Juan R Otero-Martinez
-
San Juan, Puerto Rico, 00927
- Recruiting
- FDI Clinical Research
-
Principal Investigator:
- Oscar Ruiz Bermudez
-
-
-
-
-
Galați, Romania, 800001
- Recruiting
- Milena Sante
-
Principal Investigator:
- Cristina-Victoria Mistodie
-
Galați, Romania, 800291
- Recruiting
- Diamed Obesity
-
Principal Investigator:
- Magdalena Morosanu
-
Satu Mare, Romania, 440055
- Recruiting
- Clinica Korall
-
Principal Investigator:
- Adriana Filimon
-
-
Bihor
-
Oradea, Bihor, Romania, 410147
- Recruiting
- Diabdana
-
Principal Investigator:
- Dana Cosma
-
-
Brașov
-
Brasov, Brașov, Romania, 500283
- Recruiting
- C.M.D.T.A. Neomed
-
Principal Investigator:
- Valentina Neacsu
-
-
Bucuresti
-
Bucharest, Bucuresti, Romania, 013764
- Recruiting
- Centrul Medical NutriLife
-
Principal Investigator:
- Marlena Pascu
-
-
București
-
Bucharest, București, Romania, 010627
- Recruiting
- Geea Medical Easy Diet
-
Principal Investigator:
- Georgeta Vacaru
-
Bucharest, București, Romania, 50538
- Recruiting
- Centrul Medical Endocrinologie si Diabet Dr. Paveliu
-
Principal Investigator:
- Fraga Paveliu
-
-
Maramureș
-
Baia Mare, Maramureș, Romania, 430222
- Recruiting
- CMI DNBM Dr. Pop Lavinia
-
Principal Investigator:
- Lavinia Pop
-
-
Mureș
-
Târgu Mureș, Mureș, Romania, 540098
- Recruiting
- SC Dentosim Queen SRL - Centrul Medical Diamed
-
Principal Investigator:
- Daniela Ciomos
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85286
- Recruiting
- MD First Research - Chandler
-
Principal Investigator:
- Rajiv Parikh
-
Phoenix, Arizona, United States, 85014
- Recruiting
- Phoenix Clinical LLC
-
Principal Investigator:
- Brock Adam Merritt
-
-
Arkansas
-
Bryant, Arkansas, United States, 72022
- Recruiting
- SanRo Clinical Research Group
-
Principal Investigator:
- Mark Albey
-
-
California
-
Loma Linda, California, United States, 92350
- Recruiting
- Loma Linda University Health System
-
Principal Investigator:
- Warren Peters
-
Pomona, California, United States, 91766
- Recruiting
- Western University of Health Sciences
-
Principal Investigator:
- Airani Sathananthan
-
Toluca Lake, California, United States, 91602
- Recruiting
- Med Partners, Inc. dba Premiere Medical Center of Burbank, Inc.
-
Principal Investigator:
- Michael Marsh
-
-
Connecticut
-
Hamden, Connecticut, United States, 06517
- Recruiting
- CMR of Greater New Haven
-
Principal Investigator:
- Joseph Soufer
-
-
Florida
-
Hollywood, Florida, United States, 33021
- Recruiting
- Encore Medical Research
-
Principal Investigator:
- Rodolfo A. Perez
-
Weston, Florida, United States, 33331
- Recruiting
- Encore Medical Research - Weston
-
Principal Investigator:
- Sandro Bacchelli
-
-
Georgia
-
Decatur, Georgia, United States, 30034
- Recruiting
- Orita Clinical Research
-
Principal Investigator:
- Ahmad Jingo
-
-
Idaho
-
Blackfoot, Idaho, United States, 83221
- Recruiting
- Bingham Memorial Hospital
-
Principal Investigator:
- Gary M Ullery
-
Boise, Idaho, United States, 83702
- Recruiting
- Humphreys Diabetes Center
-
Principal Investigator:
- Sherwin C D'Souza
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Recruiting
- Cotton O'Neil Clinical Research Center
-
Principal Investigator:
- susan brian
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Recruiting
- The Research Group of Lexington
-
Principal Investigator:
- Justin Arambasick
-
-
New York
-
Staten Island, New York, United States, 10310
- Recruiting
- Richmond University Medical Center
-
Principal Investigator:
- Philip Otterbeck
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Recruiting
- Velocity Clinical Research, Mt. Auburn
-
Principal Investigator:
- Matthew Wenker
-
-
Pennsylvania
-
Scottdale, Pennsylvania, United States, 15683
- Recruiting
- Frontier Clinical Research, LLC
-
Principal Investigator:
- Tiffany Michael Pluto
-
-
Tennessee
-
Memphis, Tennessee, United States, 38115
- Recruiting
- Lifedoc Research - Lenox Park Drive
-
Principal Investigator:
- Pedro Alejandro Velasquez-Mieyer
-
-
Texas
-
Shavano Park, Texas, United States, 78231
- Recruiting
- Consano Clinical Research, LLC
-
Principal Investigator:
- Michelle Welch
-
Weslaco, Texas, United States, 78596
- Recruiting
- Texas Valley Clinical Research
-
Principal Investigator:
- Eduardo Dusty Luna
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have Type 2 Diabetes (T2D)
- Have HbA1c ≥7.0% [53 mmol/mol] to ≤10.5% [91 mmol/mol]
Have been treated with stable doses of the same formulation of the following for ≥90 days prior to screening visit 1 and have maintained the same doses through randomization:
- insulin glargine U-100 (100 U/mL) ≥0.25 U/kg/QD (units per kilogram per day) or ≥20 U/QD alone, or
- insulin glargine U-100 (100 U/mL) ≥0.25 U/kg/QD or ≥20 U/QD in combination with
- metformin, or
- SGLT-2 inhibitor, or
- both metformin and SGLT-2 inhibitor.
- Are of stable body weight (±5%) for at least 90 days prior to screening visit 1 and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
- Have a Body Mass Index (BMI) ≥23.0 kg/m^2 at baseline.
Exclusion Criteria:
- Have New York Heart Association functional classification III-IV congestive heart failure.
Have had any of the following cardiovascular conditions within 60 days prior to baseline.
- acute myocardial infarction
- cerebrovascular accident (stroke), or
- hospitalization for congestive heart failure.
- Have acute or chronic hepatitis, including a history of autoimmune hepatitis, signs or symptoms of any other liver disease other than nonalcoholic fatty liver disease
- Have had chronic or acute pancreatitis any time.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants will receive placebo orally.
|
Administered orally.
|
Experimental: Orforglipron Dose 1
Participants will receive orforglipron orally.
|
Administered orally.
Other Names:
|
Experimental: Orforglipron Dose 2
Participants will receive orforglipron orally.
|
Administered orally.
Other Names:
|
Experimental: Orforglipron Dose 3
Participants will receive orforglipron orally.
|
Administered orally.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Orforglipron Dose 1, 2: Change from Baseline in Hemoglobin A1c (HbA1c)
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in Fasting Serum Glucose
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Change from Baseline in Body Weight
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Percentage Change from Baseline in Body Weight
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Percentage Change from Baseline in Triglycerides
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Orforglipron Dose 3: Change from Baseline in HbA1c
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Percentage of Participants Who Achieved HbA1c <7.0% (53 millimoles per mole (mmol/mol))
Time Frame: Baseline to Week 40
|
Baseline to Week 40
|
Percentage of Participants Who Achieved HbA1c ≤6.5% (48 mmol/mol)
Time Frame: Baseline to Week 40
|
Baseline to Week 40
|
Percentage Change from Baseline in non-HDL (non-high-density lipoprotein) Cholesterol
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Change from Baseline in Systolic Blood Pressure
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Change from Baseline in Daily Insulin Glargine Dose
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Percentage of Participants Who Achieved Weight Loss of ≥5%
Time Frame: Baseline to Week 40
|
Baseline to Week 40
|
Percentage of Participants Who Achieved Weight Loss of ≥10%
Time Frame: Baseline to Week 40
|
Baseline to Week 40
|
Percentage of Participants Who Achieved Weight Loss of ≥15% from Baseline
Time Frame: Baseline to Week 40
|
Baseline to Week 40
|
Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Domain and Summary Scores
Time Frame: Baseline, Week 40
|
Baseline, Week 40
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 10, 2023
Primary Completion (Estimated)
June 25, 2025
Study Completion (Estimated)
June 25, 2025
Study Registration Dates
First Submitted
October 26, 2023
First Submitted That Met QC Criteria
October 26, 2023
First Posted (Actual)
October 31, 2023
Study Record Updates
Last Update Posted (Actual)
April 16, 2024
Last Update Submitted That Met QC Criteria
April 15, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18567
- J2A-MC-GZGW (Other Identifier: Eli Lilly and Company)
- U1111-1294-2797 (Other Identifier: UTN Number)
- 2023-507280-18-00 (Other Identifier: EU Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD Sharing Time Frame
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later.
Data will be indefinitely available for requesting.
IPD Sharing Access Criteria
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States